CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 122 filers reported holding CRINETICS PHARMACEUTICALS IN in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $2,822,034 | +61.1% | 60,287 | +22.4% | 0.00% | +50.0% |
| Q4 2023 | $1,752,066 | +58.3% | 49,243 | +32.3% | 0.00% | +100.0% |
| Q3 2023 | $1,106,536 | +43.5% | 37,207 | -13.1% | 0.00% | 0.0% |
| Q2 2023 | $771,183 | +51.4% | 42,796 | +34.9% | 0.00% | 0.0% |
| Q1 2023 | $509,424 | -6.2% | 31,720 | +6.9% | 0.00% | 0.0% |
| Q4 2022 | $543,181 | -11.1% | 29,682 | -4.5% | 0.00% | 0.0% |
| Q3 2022 | $611,000 | +19.6% | 31,066 | +13.2% | 0.00% | 0.0% |
| Q2 2022 | $511,000 | -6.6% | 27,436 | +10.1% | 0.00% | – |
| Q1 2022 | $547,000 | -5.2% | 24,930 | +22.7% | 0.00% | – |
| Q4 2021 | $577,000 | +89.8% | 20,317 | +41.3% | 0.00% | – |
| Q3 2021 | $304,000 | +13.0% | 14,382 | +0.6% | 0.00% | – |
| Q2 2021 | $269,000 | +68.1% | 14,290 | +36.2% | 0.00% | – |
| Q1 2021 | $160,000 | -38.7% | 10,492 | -43.2% | 0.00% | – |
| Q4 2020 | $261,000 | +23.7% | 18,470 | +53.2% | 0.00% | – |
| Q2 2020 | $211,000 | – | 12,057 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 479,681 | $21,484,912 | 8.12% |
| New Leaf Venture Partners, L.L.C. | 141,000 | $6,315,390 | 7.68% |
| STEMPOINT CAPITAL LP | 551,095 | $24,683,545 | 7.25% |
| EcoR1 Capital, LLC | 4,155,375 | $186,119,246 | 5.69% |
| ACUTA CAPITAL PARTNERS, LLC | 135,141 | $6,052,965 | 5.10% |
| First Light Asset Management, LLC | 1,200,508 | $53,770,753 | 4.71% |
| Ikarian Capital, LLC | 588,818 | $26,373,158 | 4.59% |
| Paradigm Biocapital Advisors LP | 2,513,302 | $112,570,797 | 4.31% |
| MPM BioImpact LLC | 557,184 | $24,956,271 | 3.88% |
| Cormorant Asset Management, LP | 1,350,000 | $60,466,500 | 3.49% |